vaccine, mmr


Merck Sharp & Dohme


Zuellig Pharma
Concise Prescribing Info
Live measles, mumps & rubella virus vaccine
Simultaneous vaccination against measles, mumps & rubella in individuals >12 mth.
Dosage/Direction for Use
0.5 mL SC into the outer aspect of the upper arm. Do not give Ig concurrently w/ M-M-R II. Recommended vaccination schedule Individual 1st vaccinated at ≥12 mth should be revaccinated at 4-6 yr or 11-12 yr. Measles outbreak schedule Infant who are vaccinated between 6-12 mth in an outbreak situation should receive 2nd dose of M-M-R II at 15 mth, followed by revaccination at 4-6 yr or 11-12 yr.
Hypersensitivity including gelatin. Anaphylactic or anaphylactoid reactions to neomycin. Febrile resp illness or other active febrile infection. Active untreated TB. Patients receiving immunosuppressive therapy. Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. Primary & acquired immunodeficiency states including patients who are immunosuppressed in association w/ AIDS or other clinical manifestations of infection w/ HIV; cellular immune deficiencies; hypogammaglobulinemic & dysgammaglobulinemic states. MIBE, pneumonitis & death as direct consequence of disseminated measles vaccine virus infection has been reported in severely immunocompromised individuals inadvertently vaccinated w/ measles-containing vaccine. Family history of congenital or hereditary immunodeficiency until immune competence of potential vaccine recipient is demonstrated. Pregnancy. Avoid pregnancy for 3 mth following vaccination.
Special Precautions
Not to be inj IV. Individual or family histories of convulsions, history of cerebral injury or any other condition in which stress due to fever should be avoided. Allergy to eggs. Current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia w/ 1st dose of M-M-R II (or its component vaccines) may develop thrombocytopenia w/ repeat doses. Vaccinees who are infected w/ HIV should be monitored closely for vaccine-preventable diseases. If tuberculin test is to be done, it should be administered either before or simultaneously w/ M-M-R II. Lactation. Safety & effectiveness of measles vaccine in infants <6 mth have not been established. Safety & effectiveness of mumps & rubella vaccine in infants <12 mth have not been established.
Adverse Reactions
Inj site burning &/or stinging of short duration. Occasional: Fever; rash. Rare: mild local reactions eg, erythema, induration & tenderness; sore throat, malaise, atypical measles, syncope, irritability; parotitis, nausea, vomiting, diarrhea; regional lymphadenopathy, thrombocytopenia, purpura; allergic reactions eg, inj site wheal & flare, anaphylaxis & anaphylactoid reactions as well as related phenomena eg, angioneurotic edema (including peripheral or facial edema) & bronchial spasm, urticaria in individuals w/ or w/o an allergic history; arthralgia &/or arthritis (usually transient & rarely chronic), myalgia; febrile convulsions in childn, afebrile convulsions or seizures, headache, dizziness, paresthesia, polyneuritis, polyneuropathy, Guillain-Barre syndrome, ataxia, MIBE. Encephalitis/encephalopathy have been reported. Pneumonitis, cough, rhinitis; erythema multiforme, Stevens-Johnson syndrome, inj site vesiculation, swelling; forms of optic neuritis including retrobulbar neuritis, papillitis & retinitis; ocular palsies, otitis media, nerve deafness, conjunctivitis; orchitis; death from various & in some cases, unknown causes has been reported rarely following vaccination. Reports of subacute sclerosing panencephalitis in childn who did not have history of natural measles but did receive measles vaccine. Panniculitis; arthralgia &/or arthritis (usually transient & rarely chronic) & polyneuritis; reactions in joints; rarely encephalitis & encephalopathy.
Drug Interactions
ATC Classification
J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.
M-M-R II vaccine (vial)
(single dose) 0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in